ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,149.27
0.79%
Dow Jones
43,881.09
1.09%
Gold vs US Dollar
2,667.045
0.55%
Brent Oil
73.24
0.55%
Bitcoin
97,579.14
3.42%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSX
  6. Eupraxia Pharmaceuticals Inc (EPRX)

  7. Eupraxia Pharmaceuticals Inc (EPRX) News

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:TSX:EPRX
DateTimeSourceHeadlineSymbolCompany
20/11/202412:00PR Newswire (Canada)Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six MonthsTSX:EPRXEupraxia Pharmaceuticals Inc
20/11/202412:00PR Newswire (US)Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six MonthsTSX:EPRXEupraxia Pharmaceuticals Inc
14/11/202422:00PR Newswire (US)Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual MeetingTSX:EPRXEupraxia Pharmaceuticals Inc
14/11/202422:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual MeetingTSX:EPRXEupraxia Pharmaceuticals Inc
13/11/202422:00PR Newswire (Canada)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
13/11/202422:00PR Newswire (US)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
12/11/202422:56PR Newswire (US)Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
12/11/202422:56PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
07/11/202422:00PR Newswire (US)Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
07/11/202422:00PR Newswire (Canada)Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
31/10/202423:36PR Newswire (US)Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 MillionTSX:EPRXEupraxia Pharmaceuticals Inc
31/10/202423:36PR Newswire (Canada)Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 MillionTSX:EPRXEupraxia Pharmaceuticals Inc
28/10/202411:00PR Newswire (US)Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
28/10/202411:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
15/10/202411:00PR Newswire (US)Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee OsteoarthritisTSX:EPRXEupraxia Pharmaceuticals Inc
15/10/202411:00PR Newswire (Canada)Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee OsteoarthritisTSX:EPRXEupraxia Pharmaceuticals Inc
10/10/202411:00PR Newswire (US)Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024TSX:EPRXEupraxia Pharmaceuticals Inc
10/10/202411:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024TSX:EPRXEupraxia Pharmaceuticals Inc
02/10/202421:01PR Newswire (Canada)Eupraxia Pharmaceuticals Strengthens Senior Management TeamTSX:EPRXEupraxia Pharmaceuticals Inc
02/10/202421:01PR Newswire (US)Eupraxia Pharmaceuticals Strengthens Senior Management TeamTSX:EPRXEupraxia Pharmaceuticals Inc
19/09/202421:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal DiseasesTSX:EPRXEupraxia Pharmaceuticals Inc
19/09/202421:00PR Newswire (US)Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal DiseasesTSX:EPRXEupraxia Pharmaceuticals Inc
11/09/202411:00PR Newswire (US)Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
11/09/202411:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
04/09/202411:00PR Newswire (US)Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
04/09/202411:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
07/08/202421:00PR Newswire (US)Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
07/08/202421:00PR Newswire (Canada)Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
02/08/202411:00PR Newswire (US)Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt FacilityTSX:EPRXEupraxia Pharmaceuticals Inc
02/08/202411:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt FacilityTSX:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:TSX:EPRX

Your Recent History

LSE
DEC
Diversified Energy
LSE
POS
Plexus
LSE
VAST
Vast Resources
LSE
SYME
Supply@me Capital
LSE
MIN
Minoan
LSE
LIO
Liontrust Asset Management
LSE
STX
Shield Therapeutics
LSE
AAZ
Anglo Asian Mining
LSE
ITM
Itm Power
LSE
BOO
Boohoo
LSE
GGP
Greatland Gold
LSE
TERN
Tern
LSE
NEXN
Nexxen
LSE
TW.
Taylor Wimpey
LSE
MTRO
Metro Bank
LSE
THG
Thg
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Level 2 Lite

    1 year 40%, 2 years 50% and *3 years 60%
    EU Flag

    *Across 3 years £2132.64 only £853.06